Daxor to Exhibit at World's Largest Critical Care Conference

Rhea-AI Summary

Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, will exhibit at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress in Orlando, FL from February 23-25, 2025, at Booth #532.

The company's Blood Volume Analysis (BVA) technology has demonstrated significant impact in ICU settings, where there are 5.7 million annual admissions costing $108 billion in the United States. Peer-reviewed studies show BVA technology alters fluid and red blood cell interventions in 44% of cases and reduces mortality by 66% in surgical intensive care units, while also decreasing hospital stays and ventilator days.

Positive

• BVA technology demonstrates 66% mortality reduction in surgical ICUs
• Technology alters treatment decisions in 44% of cases
• Addresses large market opportunity of 5.7M annual ICU admissions worth $108B in US
• Clinical evidence supported by peer-reviewed studies including randomized controlled trial

Negative

• None.

Daxor’s Blood Volume Analysis (BVA) Technology Takes Center Stage at SCCM 2025

Oak Ridge, TN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress at the Orange County Convention Center in Orlando, FL from February 23 through February 25, 2025. The Company will be exhibiting at Booth #532.

"With 5.7 million annual ICU admissions costing $108 billion in the United States, and scores of affirming peer-reviewed studies, including a randomized controlled trial, Daxor’s blood volume analysis (BVA) has demonstrated significant impact on patient outcomes - altering fluid and red blood cell interventions in 44% of cases and reducing mortality by 66% in surgical intensive care units, while decreasing hospital stays and ventilator days. This conference offers a strategic platform to showcase how our innovative solution reshapes patient care and healthcare economics," said Michael Feldschuh, Daxor CEO and President.

About Society of Critical Care Medicine

The Society of Critical Care Medicine (SCCM) is the largest nonprofit medical organization dedicated to promoting excellence and consistency in the practice of critical care. With members in more than eighty countries, SCCM is the only organization that represents all professional components of the critical care team. The Society offers a variety of activities that ensure excellence in patient care, education, research, and advocacy.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com

FAQ

What are the clinical benefits of Daxor's (DXR) Blood Volume Analysis technology?

Daxor's BVA technology reduces mortality by 66% in surgical ICUs, alters fluid and red blood cell interventions in 44% of cases, and decreases hospital stays and ventilator days.

What is the market size for Daxor's (DXR) BVA technology in US ICUs?

The US ICU market includes 5.7 million annual admissions, representing a $108 billion market opportunity.

When and where is Daxor (DXR) exhibiting at SCCM 2025?

Daxor is exhibiting at Booth #532 at the SCCM 2025 Critical Care Congress, held at the Orange County Convention Center in Orlando, FL from February 23-25, 2025.

What clinical evidence supports Daxor's (DXR) BVA technology?

Daxor's BVA technology is supported by multiple peer-reviewed studies, including a randomized controlled trial, demonstrating significant improvements in patient outcomes.